X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs ALEMBIC LTD - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH ALEMBIC LTD PANACEA BIOTECH/
ALEMBIC LTD
 
P/E (TTM) x -20.5 53.9 - View Chart
P/BV x 2.9 3.0 94.7% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 PANACEA BIOTECH   ALEMBIC LTD
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
ALEMBIC LTD
Mar-16
PANACEA BIOTECH/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs14953 281.6%   
Low Rs8229 280.9%   
Sales per share (Unadj.) Rs84.14.7 1,782.8%  
Earnings per share (Unadj.) Rs-18.38.8 -208.7%  
Cash flow per share (Unadj.) Rs-6.79.0 -74.4%  
Dividends per share (Unadj.) Rs00.15 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs83.727.7 301.9%  
Shares outstanding (eoy) m61.25267.03 22.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.48.7 15.8%   
Avg P/E ratio x-6.34.7 -134.8%  
P/CF ratio (eoy) x-17.24.6 -378.2%  
Price / Book Value ratio x1.41.5 93.2%  
Dividend payout %01.7 0.0%   
Avg Mkt Cap Rs m7,07410,962 64.5%   
No. of employees `0002.8NA-   
Total wages/salary Rs m1,449238 608.9%   
Avg. sales/employee Rs Th1,874.1NM-  
Avg. wages/employee Rs Th527.0NM-  
Avg. net profit/employee Rs Th-407.7NM-  
INCOME DATA
Net Sales Rs m5,1541,260 408.9%  
Other income Rs m100264 37.8%   
Total revenues Rs m5,2541,524 344.7%   
Gross profit Rs m-76683 -925.5%  
Depreciation Rs m71161 1,158.0%   
Interest Rs m1,5030 501,000.0%   
Profit before tax Rs m-2,881285 -1,011.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-62,096 -0.3%   
Extraordinary Inc (Exp) Rs m1,771-32 -5,499.7%   
Tax Rs m176 275.4%   
Profit after tax Rs m-1,1212,343 -47.9%  
Gross profit margin %-14.96.6 -226.3%  
Effective tax rate %-0.62.1 -27.2%   
Net profit margin %-21.8185.9 -11.7%  
BALANCE SHEET DATA
Current assets Rs m3,8101,689 225.6%   
Current liabilities Rs m8,365486 1,720.5%   
Net working cap to sales %-88.495.4 -92.6%  
Current ratio x0.53.5 13.1%  
Inventory Days Days156217 71.8%  
Debtors Days Days6781 83.0%  
Net fixed assets Rs m14,4801,624 891.6%   
Share capital Rs m61534 11.5%   
"Free" reserves Rs m9035,960 15.2%   
Net worth Rs m5,1277,404 69.2%   
Long term debt Rs m5,832104 5,591.3%   
Total assets Rs m19,4338,010 242.6%  
Interest coverage x-0.9950.7 -0.1%   
Debt to equity ratio x1.10 8,074.0%  
Sales to assets ratio x0.30.2 168.6%   
Return on assets %2.029.3 6.7%  
Return on equity %-21.931.6 -69.1%  
Return on capital %3.631.3 11.6%  
Exports to sales %24.52.9 833.0%   
Imports to sales %10.228.9 35.3%   
Exports (fob) Rs m1,26437 3,406.5%   
Imports (cif) Rs m525364 144.3%   
Fx inflow Rs m1,53937 4,148.8%   
Fx outflow Rs m942365 258.1%   
Net fx Rs m597-328 -182.2%   
CASH FLOW
From Operations Rs m599346 173.4%  
From Investments Rs m-438-48 920.0%  
From Financial Activity Rs m-303-301 100.5%  
Net Cashflow Rs m-141-3 4,710.0%  

Share Holding

Indian Promoters % 74.5 64.0 116.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 0.2 300.0%  
FIIs % 1.3 9.7 13.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 26.1 90.4%  
Shareholders   10,259 54,701 18.8%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT LTD.  GSK PHARMA  ELDER PHARMA  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5%

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jun 25, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS